AP NEWS

CAR T Cell Therapy Market 2018-2028 - Global Forecast by Regions, Targeted Antigens, Clinical Trials/Study, Companies - ResearchAndMarkets.com

August 23, 2018

DUBLIN--(BUSINESS WIRE)--Aug 23, 2018--The “CAR T Cell Therapy Market Global Forecast by Regions, Targeted Antigens, Clinical Trials/Study, Companies, and Celgene Corporation” company profile has been added to ResearchAndMarkets.com’s offering.

CAR T Cell therapy market is expected to grow with a CAGR of over 46% in the forecast period

Year 2017 has created new milestone for the oncology patients as FDA approved the first two CD19-targeted (Chimeric Antigen Receptor) CAR T cell therapies developed by Novartis and Gilead Sciences/Kite Pharma in the United States. These two approvals will certainly help to boost the global CAR T cell therapy market as more players are looking for big opportunities to enter the market place. At present over 200 CAR T clinical trials are running or completed across various parts of the world.

Rising numbers of adults and children developing cancer, increasing government initiatives for promoting research for cell therapy in cancer and rising number of clinical trials globally are some of the key drivers for the global CAR T Cell therapy market; however high cost of CAR T cell therapy treatment and regulatory challenges are key inhibitors for this market.

This report studies the Global CAR T cell therapy market from 2 key view points by CAR T cell therapy market and CAR T cell therapy studies. Market segments are further studied by geographical regions and targeted antigens whereas CAR T cell therapy studies by targeted antigens globally and China specific. The report provides a complete analysis of the key Growth Drivers and Challenges, SWOT analysis, market, and their projections for the upcoming years (2028).

The report has been analyzed from 9 major viewpoints

1. Targeted Antigen - Global CAR T Cell Therapy Market

2. Regional CAR T Cell Therapy Market

3. Global - CAR T Cell Therapy Clinical Trials/Study

4. China CAR T Cells Clinical Trials Details

5. CAR T Cell Therapy SWOT Analysis

6. The Regulation in CAR T Cell Therapy

7. Global - IPO/Investment/Funding/Partnership in CAR T Cell Therapy Market

8. Growth Drivers and Challenges

9. Key CAR T companies Initiatives and Financial Insight

Targeted Antigens - Global CAR T Cell Therapy Market & Forecast

CD19 CD20 GD2 CD22 CD30 CD33 HER2 MESO EGFRvII Others

Regional CAR-T Cell Therapy Market & Forecast

North America Europe Asia Pacific Latin America Middle East Africa

Global - CAR T Cell Therapy Clinical Trials/Study

CD19 CD20 GD2 CD22 CD30 CD33 HER1 HER2 MESO EGFRvII

China CAR T Cells Clinical Trials Details

By Cities CAR T Cells Clinical Trials CD19 Directed CAR T Cells Clinical Trials Non-CD19 Directed CAR T Cells Clinical Trials Solid Tumors CAR T Cells Clinical Trials

The Regulation in CAR T Cell Therapy

United States European Union China

IPO/Investment/Funding/Partnership in CAR T Cell Therapy Market

Venture Capital Investment Initial Public Offerings Strategic Partnerships/Deals Key CAR T Technology Deals

Key Companies covered in this report are

Novartis Gilead Sciences (Kite Pharma) Celgene Corporation (Juno Therapeutics) Celyad

For more information about this company profile visit https://www.researchandmarkets.com/research/372757/car_t_cell?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180823005457/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Company Reports

KEYWORD:

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY ONCOLOGY

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 08/23/2018 09:36 AM/DISC: 08/23/2018 09:36 AM

http://www.businesswire.com/news/home/20180823005457/en

AP RADIO
Update hourly